Category Archives: Inflamm Bowel Dis

Inflammatory Bowel Diseases: Review of Known Environmental Protective and Risk Factors Involved.






Related Articles
Inflammatory Bowel Diseases: Review of Known Environmental Protective and Risk Factors Involved.
Inflamm Bowel Dis. 2017 Aug 02;:
Authors: van der Sloot KWJ, Amini M, Peters V, Dijkstra G, Alizadeh BZ… Continue reading

Posted in Inflamm Bowel Dis | Tagged , | Leave a comment

Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide.






Related Articles
Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide.
Inflamm Bowel Dis. 2017 Jun;23(6):894-902
Authors: … Continue reading






Posted in Inflamm Bowel Dis | Tagged , | Leave a comment

Identification of Clinical and Genetic Parameters Associated with Hidradenitis Suppurativa in Inflammatory Bowel Disease.






Identification of Clinical and Genetic Parameters Associated with Hidradenitis Suppurativa in Inflammatory Bowel Disease.

Inflamm Bowel Dis. 2015 Sep 29;

Authors: Janse IC, Koldijk MJ, Spekhorst LM, Vila AV, Weersma RK, Dijkstra G, Horváth B

Abstract
BACKGROUND: Hidradenitis suppurativa (HS) has recently been associated with inflammatory bowel disease (IBD). The objective of this study is to investigate the prevalence of HS in IBD and to identify clinical and genetic parameters associated with HS in IBD.
METHODS: A questionnaire, validated for HS, was sent to 1969 patients suffering from IBD.
RESULTS: The prevalence of HS in our IBD cohort (1260 participating patients) was significantly higher than in the general population (6.8%-10.6% versus 1%-2%). IBD patients with HS were affected by IBD significantly earlier and more often treated with anti-TNF-α therapy and surgical resection compared to IBD without HS. Female gender, smoking, a higher body mass index, and younger age were independent associated parameters for HS. Within cases allelic association analysis was performed for 59 cases (IBD with HS) and 293 controls (IBD without HS). We observed 2 promising new associations in genomic regions harboring ELOVL7 (rsnumber 10057395 P = 7.15 × 10, odds ratio = 0.4), and in the intergenic region between SULT1B1 and SULT1E1 (rsnumber 2014777 P = 7.48 × 10, odds ratio = 2.3).
CONCLUSIONS: HS is present in 6.8% to 10.6% of IBD patients. Co-morbid HS is associated with an early onset of IBD in which anti-tumor necrosis factor-α therapy and surgical resections are often needed. We identified a suggestive protective association with ELOVL7 and suggestive risk association with the genes SULT1B1 and SULT1E1 for HS, in the context of IBD. These genetic associations need further exploration and replication in additional independent cohorts.

PMID: 26422515 [PubMed – as supplied by publisher]

Continue reading






Posted in Inflamm Bowel Dis | Leave a comment

Predicting Endoscopic Disease Activity in Crohn’s Disease: A New and Validated Noninvasive Disease Activity Index (The Utrecht Activity Index).






Predicting Endoscopic Disease Activity in Crohn’s Disease: A New and Validated Noninvasive Disease Activity Index (The Utrecht Activity Index).

Inflamm Bowel Dis. 2015 Jul 15;

Authors: Minderhoud IM, Steyerberg EW, van Bodegraven AA, van der Woude CJ, Hommes DW, Dijkstra G, Fidder HH, Schwartz MP, Oldenburg B, Dutch Initiative on Crohnʼs and Colitis (ICC)

Abstract
BACKGROUND: Mucosal healing is presently considered one of the primary goals in treatment of Crohn’s disease (CD), but this can only be confirmed by endoscopy. We aimed to design and validate a new disease activity index based on a combination of clinical characteristics and readily available laboratory parameters, which reliably predicts the presence and severity of endoscopic disease activity in patients with CD.
METHODS: Thirteen clinical characteristics and laboratory variables were selected for analysis. Endoscopic disease activity was assessed by the Crohn’s disease Endoscopic Index of Severity. A linear regression model was based on 93 ileocolonoscopies performed in 82 patients with CD and internally validated by bootstrap resampling. Subsequently, the newly developed model was validated in a cohort of 99 patients.
RESULTS: The number of liquid stools during 1 day × 0.25 + C-reactive protein (in milligrams per liter) × 0.1 + platelet count (×10/L) × 0.01 + fecal calprotectin (in milligrams per liter) × 0.001 – mean platelet volume (in femtoliters) × 0.2 optimally predicted the severity of endoscopic disease activity (bootstrap adjusted R = 0.50). The model demonstrated good agreement in the external validation (r = 0.7), especially for (ileo)colonic CD (r = 0.8). Using receiver operator characteristic statistics, a cutoff point of 3 on the new index indicated endoscopic disease activity with a sensitivity of 80% and a specificity of 92%.
CONCLUSIONS: This newly developed, noninvasive, index was found to reliably predict endoscopic disease activity in patients with CD. This tool can facilitate clinical decision making and might prove valuable in clinical trials.

PMID: 26181428 [PubMed – as supplied by publisher]

Continue reading






Posted in Inflamm Bowel Dis | Leave a comment

Out-of-pocket Cost Burden in Pediatric Inflammatory Bowel Disease: A Cross-sectional Cohort Analysis.






Out-of-pocket Cost Burden in Pediatric Inflammatory Bowel Disease: A Cross-sectional Cohort Analysis.
Inflamm Bowel Dis. 2015 Apr 1;
Authors: Sin AT, Damman JL, Ziring DA, Gleghorn EE, Garcia-Careaga MG, Gugig RR, Hu… Continue reading






Posted in Inflamm Bowel Dis | Tagged | Leave a comment

IL-22-STAT3 Pathway Plays a Key Role in the Maintenance of Ileal Homeostasis in Mice Lacking Secreted Mucus Barrier.






IL-22-STAT3 Pathway Plays a Key Role in the Maintenance of Ileal Homeostasis in Mice Lacking Secreted Mucus Barrier.

Inflamm Bowel Dis. 2015 Jan 29;

Authors: Sovran B, Loonen LM, Lu P, Hugenholtz F, Belzer C, Stolte EH, Boekschoten MV, van Baarlen P, Kleerebezem M, de Vos P, Dekker J, Renes IB, Wells JM

Abstract
BACKGROUND:: Muc2-deficient mice show no signs of ileal pathology but the mechanisms remained unknown.
METHODS:: Wild-type (WT), Muc2, and Muc2 mice were killed at 2, 4, and 8 weeks of age. Total RNA from ileum was used for full genome transcriptome analysis and qPCR. Microbiota composition was determined using a mouse intestinal chip (MITChip). Morphological and immunohistological studies were performed on segments of ileum.
RESULTS:: The ileum was colonized by more diverse microbiota in young (week 4) WT than in Muc2 mice, and composition was influenced by genotype. Weaning was associated with major changes in the transcriptome of all mice, and the highest number of differentially expressed genes compared with adults, reflecting temporal changes in microbiota. Although the spatial compartmentalization of bacteria was compromised in Muc2 mice, gene set enrichment analysis revealed a downregulation of Toll-like receptor, immune, and chemokine signaling pathways compared to WT mice. The predicted effects of enhanced IL-22 signaling were identified in the Muc2 transcriptome as the upregulation of epithelial cell proliferation altered expression of mitosis and cell-cycle control pathways. This is consistent with increased villus length and number of Ki67 epithelial cells in Muc2 mice. Additionally, expression of the network of IL-22 regulated defense genes, including Fut2, Reg3β, Reg3γ, Relmb, and the Defensin Defb46 were increased in Muc2 mice.
CONCLUSIONS:: These findings highlight a role for the IL-22-STAT3 pathway in maintaining ileal homeostasis when the mucus barrier is compromised and its potential as a target for novel therapeutic strategies in inflammatory bowel disease.

PMID: 25636123 [PubMed – as supplied by publisher]

Continue reading






Posted in Inflamm Bowel Dis | Tagged , | Leave a comment

Self-reported Disability in Patients with Inflammatory Bowel Disease Largely Determined by Disease Activity and Illness Perceptions.






Self-reported Disability in Patients with Inflammatory Bowel Disease Largely Determined by Disease Activity and Illness Perceptions.
Inflamm Bowel Dis. 2015 Jan 7;
Authors: van der Have M, Fidder HH, Leenders M, Kapt… Continue reading






Posted in Inflamm Bowel Dis | Leave a comment

Thiopurines are associated with a reduction in surgical re-resections in patients with Crohn’s disease: a long-term follow-up study in a regional and academic cohort.






Related Articles

Thiopurines are associated with a reduction in surgical re-resections in patients with Crohn’s disease: a long-term follow-up study in a regional and academic cohort.

Inflamm Bowel Dis. 2013 Dec;19(13):2801-8

Authors: van Loo ES, Vosseberg NW, van der Heide F, Pierie JP, van der Linde K, Ploeg RJ, Dijkstra G, Nieuwenhuijs VB

Abstract
BACKGROUND: Combination therapy of thiopurines and anti-tumor necrosis factor alpha (TNF-α) antibodies is the most effective medical treatment of Crohn’s disease (CD). Data on thiopurines and anti-TNF-α antibodies in preventing surgical recurrence (need for re-resection) of CD are scarce. Therefore, we analyzed which factors were involved in surgical recurrence of CD in a large cohort of patients with CD operated in a regional and a university hospital.
METHODS: This is a retrospective cohort study of 567 patients who underwent surgery for CD. Clinical data and risk factors for surgical recurrence were analyzed, focusing on medical therapy and hospital type.
RESULTS: Overall, 237 (41.8%) patients developed a surgical recurrence, after a median of 70 (2-482) months. Before surgical recurrence, 235 patients (41.4%) and 116 patients (20.5%) used thiopurines and anti-TNF-α antibodies, respectively. Multivariate analysis identified 3 independent risk factors associated with surgical recurrence of CD. A higher risk was seen in patients with colonic disease compared with patients with ileal disease (hazard ratio, 1.56; 95% confidence interval, 1.10-2.21; P = 0.012) and in patients using multiple types of medication (hazard ratio, 1.38; 95% confidence interval, 1.25-1.54; P < 0.001). However, a lower risk was seen in patients using thiopurines (hazard ratio, 0.51; 95% confidence interval, 0.34-0.77; P = 0.001).
CONCLUSIONS: Thiopurines are effective in preventing surgical recurrence of CD. The role of anti-TNF-α antibodies seems promising as well. Combination therapy of thiopurines and anti-TNF-α antibodies for prevention of surgical recurrence of CD should be studied in a randomized trial.

PMID: 24189041 [PubMed – indexed for MEDLINE]

Continue reading






Posted in Inflamm Bowel Dis | Tagged , | Leave a comment

Do Not Read Single Calprotectin Measurements in Isolation When Monitoring Your Patients with Inflammatory Bowel Disease.






Do Not Read Single Calprotectin Measurements in Isolation When Monitoring Your Patients with Inflammatory Bowel Disease.
Inflamm Bowel Dis. 2014 Jun 30;
Authors: van Rheenen P
PMID: 24983987 [PubMed – as supp… Continue reading






Posted in Inflamm Bowel Dis | Tagged , | Leave a comment

Exploring associations of 6-thioguanine nucleotide levels and other predictive factors with therapeutic response to azathioprine in pediatric patients with IBD using multilevel analysis.






Related Articles

Exploring associations of 6-thioguanine nucleotide levels and other predictive factors with therapeutic response to azathioprine in pediatric patients with IBD using multilevel analysis.

Inflamm Bowel Dis. 2013 Oct;19(11):2404-10

Authors: Nguyen TV, Vu DH, Nguyen TM, Lachaux A, Boulieu R

Abstract
BACKGROUND: Metabolite monitoring and response predictors to azathioprine (AZA) in pediatric inflammatory bowel disease (IBD) are debatable. In an attempt to optimize thiopurine therapy and understand the mechanism of action of thiopurines, we correlated metabolites and other factors with AZA efficacy in children with IBD.
METHODS: Data from 86 children with IBD with 440 metabolite measurements were retrospectively analyzed using multilevel logistic regression analyses. A therapeutic response was defined as a pediatric Crohn’s disease activity index ≤10 for Crohn’s disease or a pediatric ulcerative colitis activity index ≤10 for ulcerative colitis without any treatment with steroids, antitumor necrosis factor, other immunomodulators, or exclusive enteral nutrition.
RESULTS: The 6-thioguanine nucleotide levels >250 pmol per 8 × 10 red blood cells correlated with a higher response (odds ratio, 4.14; 95% confidence interval, 1.49-11.46, P = 0.007), whereas 6-methyl-mercaptopurine and 6-methyl-mercaptopurine:6-thioguanine nucleotide ratio showed no correlation. Other novel response predictors in children with IBD were relative leukopenia (odds ratio, 14.01; 95% confidence interval, 3.77-52.10; P < 0.001) and the absence of lymphopenia (odds ratio, 3.71; 95% confidence interval, 1.26-10.89; P = 0.017). Lower thiopurine methyltransferase activity (P = 0.015), lower platelet count (P = 0.020), and higher aspartate aminotransferase level (P = 0.009) also predicted therapeutic response. Age, gender, patient adherence, the duration of AZA therapy, IBD type, erythrocyte count, and erythrocyte sedimentation rate did not predict efficacy. The high interindividual variability accounting for 57.7% of variance in therapeutic response was observed.
CONCLUSIONS: The significant 6-thioguanine nucleotide level-response relationship may support metabolite monitoring to improve thiopurine efficacy in pediatric IBD. The reported response predictors may be helpful for treatment optimization in AZA-treated children with IBD, but should be proved in prospective studies.

PMID: 24013359 [PubMed – indexed for MEDLINE]

Continue reading






Posted in Inflamm Bowel Dis | Tagged , | Leave a comment

Extraintestinal Manifestations and Complications in Inflammatory Bowel Disease: From Shared Genetics to Shared Biological Pathways.






Extraintestinal Manifestations and Complications in Inflammatory Bowel Disease: From Shared Genetics to Shared Biological Pathways.
Inflamm Bowel Dis. 2014 Apr 15;
Authors: van Sommeren S, Janse M, Karjalainen J, Feh… Continue reading






Posted in Inflamm Bowel Dis | Tagged , | Leave a comment

Correlation of Genetic Risk and Messenger RNA Expression in a Th17/IL23 Pathway Analysis in Inflammatory Bowel Disease.






Related Articles

Correlation of Genetic Risk and Messenger RNA Expression in a Th17/IL23 Pathway Analysis in Inflammatory Bowel Disease.

Inflamm Bowel Dis. 2014 Mar 20;

Continue reading






Posted in Inflamm Bowel Dis | Tagged | Leave a comment

Effect of Aging on Healthcare Costs of Inflammatory Bowel Disease: A Glimpse into the Future.






Related Articles

Effect of Aging on Healthcare Costs of Inflammatory Bowel Disease: A Glimpse into the Future.

Inflamm Bowel Dis. 2014 Feb 10;

Authors: van der Have M,…

Continue reading






Posted in Inflamm Bowel Dis | Tagged | Leave a comment

When independent healthcare behaviors develop in adolescents with inflammatory bowel disease.






Related Articles

When independent healthcare behaviors develop in adolescents with inflammatory bowel disease.

Inflamm Bowel Dis. 2012 Dec;18(12):2310-4

Authors: van…

Continue reading






Posted in Inflamm Bowel Dis | Tagged | Leave a comment

Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control.






Related Articles

Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control.

Inflamm Bowel Dis. 2012…

Continue reading






Posted in Inflamm Bowel Dis | Tagged | Leave a comment

Adenomas in Patients with Inflammatory Bowel Disease Are Associated with an Increased Risk of Advanced Neoplasia.






Adenomas in Patients with Inflammatory Bowel Disease Are Associated with an Increased Risk of Advanced Neoplasia.

Inflamm Bowel Dis. 2013 Jan 21;

Authors: van Schaik FD, Mooiweer…

Continue reading






Posted in Inflamm Bowel Dis | Tagged | Leave a comment

HNF4α and CDH1 are associated with ulcerative colitis in a Dutch cohort.






HNF4α and CDH1 are associated with ulcerative colitis in a Dutch cohort.

Inflamm Bowel Dis. 2011 Aug;17(8):1714-8

Authors: van Sommeren S, Visschedijk MC, Festen EA, de Jong DJ,…

Continue reading






Posted in Inflamm Bowel Dis | Tagged | Leave a comment